MA38069A1 - Composés hétéroaromatiques utilisés comme ligands de la dopamine d1 - Google Patents
Composés hétéroaromatiques utilisés comme ligands de la dopamine d1Info
- Publication number
- MA38069A1 MA38069A1 MA38069A MA38069A MA38069A1 MA 38069 A1 MA38069 A1 MA 38069A1 MA 38069 A MA38069 A MA 38069A MA 38069 A MA38069 A MA 38069A MA 38069 A1 MA38069 A1 MA 38069A1
- Authority
- MA
- Morocco
- Prior art keywords
- disease
- disorder
- cognitive impairment
- cognitive
- schizophrenia
- Prior art date
Links
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 title 2
- 229960003638 dopamine Drugs 0.000 title 1
- 150000002390 heteroarenes Chemical class 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
- 208000010877 cognitive disease Diseases 0.000 abstract 3
- 208000028698 Cognitive impairment Diseases 0.000 abstract 2
- 208000018737 Parkinson disease Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000000980 schizophrenia Diseases 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 206010020710 Hyperphagia Diseases 0.000 abstract 1
- 206010034158 Pathological gambling Diseases 0.000 abstract 1
- 208000005793 Restless legs syndrome Diseases 0.000 abstract 1
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 abstract 1
- 230000007000 age related cognitive decline Effects 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 abstract 1
- 208000029560 autism spectrum disease Diseases 0.000 abstract 1
- 230000001149 cognitive effect Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 208000024714 major depressive disease Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 208000027061 mild cognitive impairment Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000001050 pharmacotherapy Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Addiction (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Child & Adolescent Psychology (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
Abstract
La présente invention porte, en partie, sur des composés de formule i et leurs seuls pharmaceutiquement acceptables et les n-oxydes de ceux-ci ; sur des procédés pour leur préparation ; sur des intermédiaires utilisés dans leur préparation ; et sur des compositions contenant de tels composés, sels ou n-oxydes et sur leurs utilisations pour le traitement de troubles à médiation par d1 (ou associés à d1) notamment, par exemple, la schizophrénie (par exemple ses symptômes cognitifs et négatifs), une déficience cognitive (par exemple une déficience cognitive associée à la schizophrénie, à la maladie d'alzheimer, à la maladie de parkinson ou à une pharmacothérapie), le trouble d'hyperactivité avec déficit de l'attention (thada), l'impulsivité, le jeu compulsif, l'hyperphagie, un trouble du spectre de l'autisme, un trouble cognitif léger (tlc), un déclin cognitif lié à l'âge, la démence, le syndrome des jambes sans repos, la maladie de parkinson, la chorée de huntington, l'anxiété, la dépression, un trouble dépressif majeur, une dépression réfractaire au traitement (drt) et un trouble bipolaire.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261723995P | 2012-11-08 | 2012-11-08 | |
| PCT/IB2013/059768 WO2014072882A1 (fr) | 2012-11-08 | 2013-10-30 | Composés hétéroaromatiques utilisés comme ligands de la dopamine d1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA38069A1 true MA38069A1 (fr) | 2016-10-31 |
Family
ID=49955424
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA38069A MA38069A1 (fr) | 2012-11-08 | 2015-05-05 | Composés hétéroaromatiques utilisés comme ligands de la dopamine d1 |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US8822494B2 (fr) |
| EP (1) | EP2917216B1 (fr) |
| JP (1) | JP5823657B1 (fr) |
| KR (1) | KR101660664B1 (fr) |
| CN (1) | CN104837839A (fr) |
| AP (1) | AP3861A (fr) |
| AR (1) | AR095359A1 (fr) |
| AU (1) | AU2013343105B2 (fr) |
| BR (1) | BR112015010412A2 (fr) |
| CA (1) | CA2889572C (fr) |
| CL (1) | CL2015001233A1 (fr) |
| CO (1) | CO7350619A2 (fr) |
| CR (1) | CR20150237A (fr) |
| EA (1) | EA201500402A1 (fr) |
| ES (1) | ES2652514T3 (fr) |
| GE (1) | GEP201606598B (fr) |
| HK (1) | HK1213256A1 (fr) |
| IL (1) | IL238712A0 (fr) |
| MA (1) | MA38069A1 (fr) |
| MD (1) | MD20150037A2 (fr) |
| MX (1) | MX2015005506A (fr) |
| NI (1) | NI201500066A (fr) |
| PE (1) | PE20150966A1 (fr) |
| PH (1) | PH12015500883A1 (fr) |
| SG (1) | SG11201502884TA (fr) |
| TN (1) | TN2015000167A1 (fr) |
| TW (1) | TWI577678B (fr) |
| UA (1) | UA111687C2 (fr) |
| UY (1) | UY35129A (fr) |
| WO (1) | WO2014072882A1 (fr) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014072881A1 (fr) | 2012-11-08 | 2014-05-15 | Pfizer Inc. | Composés hétéroaromatiques et leur utilisation comme ligands de la dopamine d1 |
| CA2889572C (fr) * | 2012-11-08 | 2019-03-05 | Pfizer Inc. | Composes heteroaromatiques utilises comme ligands de la dopamine d1 |
| PE20160664A1 (es) | 2013-06-27 | 2016-07-09 | Pfizer | Compuestos heteroaromaticos y su uso como ligandos d1 de dopamina |
| WO2015162518A1 (fr) * | 2014-04-25 | 2015-10-29 | Pfizer Inc. | Composes hetero-aromatiques et leur utilisation comme ligands d1 de la dopamine |
| JP6239149B2 (ja) | 2014-04-25 | 2017-11-29 | ファイザー・インク | 複素芳香族化合物およびそのドーパミンｄ１リガンドとしての使用 |
| SG11201607990QA (en) | 2014-04-25 | 2016-11-29 | Pfizer | Heteroaromatic compounds and their use as dopamine d1 ligands |
| EP3137454A1 (fr) | 2014-04-28 | 2017-03-08 | Pfizer Inc. | Composés hétéroaromatiques et leur utilisation en tant que ligands de la dopamine d1 |
| CA2946990A1 (fr) | 2014-04-28 | 2015-11-05 | Pfizer Inc. | Composes heterocycliques et leur utilisation comme ligands des recepteurs d1 de la dopamine |
| CN103992319B (zh) * | 2014-05-27 | 2015-09-16 | 天津市斯芬克司药物研发有限公司 | 一种吡啶羧酸类化合物的制备方法 |
| AU2018258117A1 (en) | 2017-04-24 | 2019-12-12 | Chase Therapeutics Corporation | Compositions and method for treating depression |
| CN111182898B (zh) * | 2017-06-28 | 2024-04-16 | Ptc医疗公司 | 用于治疗亨廷顿氏病的方法 |
| AU2018290889B2 (en) | 2017-06-30 | 2024-06-27 | Alto Neuroscience, Inc. | NK-1 antagonist compositions and methods for use in treating depression |
| US20210393621A1 (en) | 2018-10-26 | 2021-12-23 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| UA130412C2 (uk) | 2020-06-22 | 2026-02-11 | Ф. Хоффманн-Ля Рош Аг | Похідні сульфону |
| CN115340500A (zh) * | 2021-05-14 | 2022-11-15 | 广东东阳光药业有限公司 | 一种含硫化合物的制备方法 |
| CN118401513A (zh) * | 2022-01-29 | 2024-07-26 | 苏州科睿思制药有限公司 | 他伐帕敦的晶型及其制备方法和用途 |
| CN114751855B (zh) * | 2022-05-23 | 2024-05-07 | 上海皓鸿生物医药科技有限公司 | 一种2-溴-4-氨基-5-甲基吡啶的制备方法 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US6395733B1 (en) | 1995-06-07 | 2002-05-28 | Pfizer Inc | Heterocyclic ring-fused pyrimidine derivatives |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035298A1 (fr) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing-gum contenant des agents medicamenteux actifs |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| US6232320B1 (en) | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
| TW200400034A (en) | 2002-05-20 | 2004-01-01 | Bristol Myers Squibb Co | Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors |
| SE0201980D0 (sv) | 2002-06-24 | 2002-06-24 | Astrazeneca Ab | Novel compounds |
| SE0301906D0 (sv) | 2003-06-26 | 2003-06-26 | Astrazeneca Ab | New compounds |
| KR20060056944A (ko) | 2003-07-14 | 2006-05-25 | 아레나 파마슈티칼스, 인크. | 대사 조절제로서 융합된 아릴 및 헤테로아릴 유도체 및이에 관련된 장애의 예방 또는 치료 |
| CA2572331A1 (fr) | 2004-07-02 | 2006-02-09 | Exelixis, Inc. | Modulateurs de c-met et leur methode d'utilisation |
| ATE501148T1 (de) | 2004-12-14 | 2011-03-15 | Astrazeneca Ab | Pyrazolopyrimidinverbindungen als antitumormittel |
| US20090048285A1 (en) * | 2005-01-19 | 2009-02-19 | Benjamin Pelcman | Pyrrolopyridines Useful in the Treatment of Inflammation |
| WO2007035428A1 (fr) | 2005-09-15 | 2007-03-29 | Bristol-Myers Squibb Company | Inhibiteurs de la kinase met |
| WO2007081517A2 (fr) | 2005-12-21 | 2007-07-19 | Abbott Laboratories | Composes anti-viraux |
| US7723330B2 (en) | 2006-03-07 | 2010-05-25 | Array Biopharma Inc. | Heterobicyclic pyrazole compounds and methods of use |
| US7601716B2 (en) | 2006-05-01 | 2009-10-13 | Cephalon, Inc. | Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors |
| WO2008037607A1 (fr) | 2006-09-25 | 2008-04-03 | Basf Se | Composés hétérocycliques à teneur en groupe carbonyle et leur utilisation pour lutter contre des champignons phytopathogènes |
| WO2008057402A2 (fr) | 2006-11-02 | 2008-05-15 | Cytovia, Inc. | N-aryl-isoxazolopyrimidin-4-amines et composés associés servant d'activateurs de caspases et d'inducteurs d'apoptose et leur utilisation |
| WO2008089307A2 (fr) | 2007-01-18 | 2008-07-24 | Lexicon Pharmaceuticals, Inc. | Méthodes et compositions utilisés dans le traitement de la douleur, de l'inflammation et du cancer |
| US20080200458A1 (en) | 2007-01-18 | 2008-08-21 | Joseph Barbosa | Methods and compositions for the treatment of body composition disorders |
| US8338437B2 (en) | 2007-02-28 | 2012-12-25 | Methylgene Inc. | Amines as small molecule inhibitors |
| US8557830B2 (en) | 2007-06-07 | 2013-10-15 | Amgen Inc. | RAF kinase modulators and methods of use |
| US7829567B2 (en) | 2007-10-31 | 2010-11-09 | Kaohsiung Medical University | Imino-indeno[1,2-c] quinoline derivatives, their preparation processes, and pharmaceutical compositions comprising the same |
| MX2010006243A (es) | 2007-12-06 | 2010-08-31 | Schering Corp | Moduladores de gamma secretasa. |
| UY31984A (es) | 2008-07-16 | 2010-02-26 | Boehringer Ingelheim Int | DERIVADOS DE 1-(3,4-difluorobencil)-6-oxo-1,6-dihidropirimidin-5-carboxamidas N-sustituidas y de 2-(3,4-difluorobencil)-3-oxo-2,3-dihidro-1H-pirazol-4-carboxamidas N-sustituidas. |
| UY31982A (es) | 2008-07-16 | 2010-02-26 | Boehringer Ingelheim Int | Derivados de 1,2-dihidropiridin-3-carboxamidas n-sustituidas |
| AR073739A1 (es) | 2008-09-10 | 2010-12-01 | Kalypsys Inc | Aminopirimidinas como inhibidores de los receptores de histamina |
| US9006252B2 (en) | 2008-09-26 | 2015-04-14 | National Health Research Institutes | Fused multicyclic compounds as protein kinase inhibitors |
| EP2408772B1 (fr) * | 2009-03-19 | 2015-07-01 | Medical Research Council Technology | Composés |
| WO2010118367A2 (fr) | 2009-04-10 | 2010-10-14 | Progenics Pharmaceuticals, Inc. | Pyrimidines antivirales |
| WO2010144586A1 (fr) | 2009-06-09 | 2010-12-16 | Abraxis Bioscience, Llc | Dérivés de l'isoquinoléine, de la quinoléine et de la quinazoléine servant d'inhibiteurs de signal hedgehog |
| CA2768843A1 (fr) | 2009-07-21 | 2011-01-27 | Gilead Calistoga Llc | Traitement de troubles du foie par des inhibiteurs de pi3k |
| TW201111385A (en) | 2009-08-27 | 2011-04-01 | Biocryst Pharm Inc | Heterocyclic compounds as janus kinase inhibitors |
| GB201008134D0 (en) | 2010-05-14 | 2010-06-30 | Medical Res Council Technology | Compounds |
| US8299117B2 (en) | 2010-06-16 | 2012-10-30 | Metabolex Inc. | GPR120 receptor agonists and uses thereof |
| MX2012015135A (es) | 2010-07-01 | 2013-05-06 | Amgen Inc | Compuestos heterociclicos y su uso como inhibidores de la actividad pi3k. |
| JP2013533884A (ja) | 2010-07-02 | 2013-08-29 | アムジエン・インコーポレーテツド | Ｐｉ３ｋ活性阻害剤としての複素環化合物およびそれらの使用 |
| WO2014072881A1 (fr) * | 2012-11-08 | 2014-05-15 | Pfizer Inc. | Composés hétéroaromatiques et leur utilisation comme ligands de la dopamine d1 |
| CA2889572C (fr) * | 2012-11-08 | 2019-03-05 | Pfizer Inc. | Composes heteroaromatiques utilises comme ligands de la dopamine d1 |
-
2013
- 2013-10-30 CA CA2889572A patent/CA2889572C/fr active Active
- 2013-10-30 JP JP2015540249A patent/JP5823657B1/ja active Active
- 2013-10-30 UA UAA201504509A patent/UA111687C2/uk unknown
- 2013-10-30 SG SG11201502884TA patent/SG11201502884TA/en unknown
- 2013-10-30 PE PE2015000612A patent/PE20150966A1/es not_active Application Discontinuation
- 2013-10-30 CN CN201380063892.3A patent/CN104837839A/zh active Pending
- 2013-10-30 ES ES13820925.9T patent/ES2652514T3/es active Active
- 2013-10-30 AP AP2015008382A patent/AP3861A/en active
- 2013-10-30 WO PCT/IB2013/059768 patent/WO2014072882A1/fr not_active Ceased
- 2013-10-30 BR BR112015010412A patent/BR112015010412A2/pt not_active IP Right Cessation
- 2013-10-30 GE GEAP201313820A patent/GEP201606598B/en unknown
- 2013-10-30 HK HK16101174.8A patent/HK1213256A1/zh unknown
- 2013-10-30 AU AU2013343105A patent/AU2013343105B2/en not_active Ceased
- 2013-10-30 EA EA201500402A patent/EA201500402A1/ru unknown
- 2013-10-30 EP EP13820925.9A patent/EP2917216B1/fr active Active
- 2013-10-30 KR KR1020157014721A patent/KR101660664B1/ko not_active Expired - Fee Related
- 2013-10-30 MD MDA20150037A patent/MD20150037A2/ro not_active Application Discontinuation
- 2013-10-30 MX MX2015005506A patent/MX2015005506A/es unknown
- 2013-11-05 US US14/072,563 patent/US8822494B2/en active Active
- 2013-11-07 AR ARP130104095A patent/AR095359A1/es unknown
- 2013-11-07 TW TW102140555A patent/TWI577678B/zh not_active IP Right Cessation
- 2013-11-08 UY UY0001035129A patent/UY35129A/es not_active Application Discontinuation
-
2014
- 2014-07-23 US US14/339,123 patent/US9133190B2/en active Active
-
2015
- 2015-04-21 PH PH12015500883A patent/PH12015500883A1/en unknown
- 2015-04-30 TN TNP2015000167A patent/TN2015000167A1/fr unknown
- 2015-05-05 MA MA38069A patent/MA38069A1/fr unknown
- 2015-05-07 IL IL238712A patent/IL238712A0/en unknown
- 2015-05-07 CL CL2015001233A patent/CL2015001233A1/es unknown
- 2015-05-07 NI NI201500066A patent/NI201500066A/es unknown
- 2015-05-08 CR CR20150237A patent/CR20150237A/es unknown
- 2015-05-08 CO CO15105499A patent/CO7350619A2/es unknown
- 2015-08-06 US US14/819,541 patent/US9527843B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2015000167A1 (fr) | Composés hétéroaromatiques utilisés comme ligands de dopamine d1 | |
| MA38661A1 (fr) | Composés hétéro-aromatiques et leur utilisation en tant que ligands d1 de la dopamine | |
| MA34361B1 (fr) | Dérivés de tétrahydro-pyrido-pyrimidine | |
| TN2013000349A1 (fr) | Imidazo[5,1-f][1,2,4] triazines pour le traitement de troubles neurologiques | |
| MX2015011313A (es) | Compuestos perfluorados de 5,6-dihidro-4h-1,3-oxazin-2-amina como inhibidores de beta-secretasa y metodos de uso. | |
| MA38090B1 (fr) | Dérivés de 5-fluoro-n-(pyridin -2-yl)pyridin-2-amines contenant un groupe sulfoximine | |
| MA37798B1 (fr) | 4-méthyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphtalènes | |
| MA42239B1 (fr) | Nouveaux dérivés d'hydroxyester, leur procédé de préparation et compositions pharmaceutiques les contenant | |
| MA40955A (fr) | 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 | |
| MA35826B1 (fr) | Triazolopyridines substituées et leur utilisation à titre d'inhibiteurs de ttk | |
| TN2009000551A1 (fr) | Nouveaux composes chimiques | |
| MA41562B1 (fr) | Agonistes d'apj 4-hydroxy-3-(heteroaryl)pyridine-2-one a utiliser dans le traitement de troubles cardio-vasculaires | |
| MA32035B1 (fr) | Composes tricycliques servant de modulateurs de synthese de tnf-alpha et d'inhibiteurs de pde4 | |
| EA200971050A1 (ru) | Способы лечения и предупреждения нейродегенеративных заболеваний и нарушений | |
| MA38079A1 (fr) | Composés de 2-phényl-5-hétérocyclyl-tétrahydro-2h-pyran-3-amine destinés à être utilisés dans le traitement du diabète et de ses troubles associés | |
| TN2015000347A1 (fr) | Azabenzimidazoles servant d'inhibiteurs d'isoenzymes pde4 pour le traitement de troubles du snc et d'autres troubles | |
| MA29411B1 (fr) | 1h-quinazoline -2,4-diones et leur utilisation en tant que ligands du recepteur ampa | |
| MA38091B1 (fr) | Dérivés n-(pyridin-2-yl)pyrimidin-4-amines contenant un groupe sulfoximine | |
| MA32506B1 (fr) | Nouveaux composes | |
| MA34384B1 (fr) | Composés hétérocycliques, leur préparation et leur application thérapeutique | |
| ATE543494T1 (de) | Griseofulvin-analoga zur behandlung von krebs durch hemmung von zentrosomaler clusterbildung | |
| EA201491116A1 (ru) | Производные 6-дифторметил-5,6-дигидро-2h-[1,4]оксазин-3-амина | |
| MA35133B1 (fr) | Dérivés d'éthynyle comme modulateurs allostériques positifs de mglur5 | |
| MA46611A (fr) | Traitements combinés comprenant des imidazopyrazinones pour le traitement de troubles psychiatriques et/ou cognitifs | |
| MA41494B1 (fr) | Composés benzoxaborole substitués en position 4 et utilisations associées |